By Sabela Ojea
Shares of Allurion Technologies on Friday surged a day after the company said it received positive results about the effectiveness of its gastric balloon in combination with a low dose of the weight-loss and type 2 diabetes therapy GLP-1.
The stock was up 40% to $3.20 in morning trading. Shares have, however, dropped 93% over the past 12 months.
The weight-loss technology company said that the results indicated the combination increases weight loss and the patients didn't experience as many side effects, such as muscle wasting, and had improve adherence.
Muscle wasting and lack of adherence are significant challenges for GLP-1 therapies, Allurion Chief Executive Shantanu Gaur said.
"We plan on building upon this promising initial data and are optimistic that this could become a new standard of care for patients who want metabolically healthy weight loss," Gaur said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
March 21, 2025 11:02 ET (15:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。